Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS).

Saved in:
Bibliographic Details
Title: Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS).
Authors: Man L; Department of Medicine, University of Virginia, Charlottesville, Virginia, USA., Kanack AJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Mauch EE; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Splinter NP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Padmanabhan A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Source: American journal of hematology [Am J Hematol] 2025 Dec; Vol. 100 (12), pp. 2377-2381. Date of Electronic Publication: 2025 Sep 13.
Publication Type: Letter
Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1096-8652
DOI:10.1002/ajh.70078